Literature DB >> 2709520

Surface interaction between glycosaminoglycans and calcium oxalate.

A H Angell1, M I Resnick.   

Abstract

Molecules and macromolecules are known to alter the process of crystallization, either through inhibition or promotion of nucleation, growth, and/or aggregation. One particular group of macromolecules, glycosaminoglycans (GAGs), has been of interest in our laboratory. The GAGs chondroitin A, chondroitin C, heparan sulfate, dermatan sulfate, hyaluronic acid, and keratan sulfate have all been shown to be inhibitors of calcium oxalate crystallization. Heparin, the only GAG which is not naturally present in urine, is the most potent inhibitor of all GAGs. Using the method of Langmuir isotherm adsorption, we studied the adsorption of certain GAGs onto calcium oxalate crystals. Under standardized conditions, heparin, chondroitin C, hyaluronic acid, and pentosan polysulfate (a synthetic polyanionic molecule similar to, but a weaker inhibitor than, heparin) were adsorbed onto calcium oxalate. The total amount of GAG required to maximally cover the crystal surface, as well as the equilibrium concentration at which surface was half-covered with GAG (inversely related to the desorption energy) were measured. Chondroitin C was adsorbed in the greatest amount, followed by heparin, pentosan polysulfate, and finally hyaluronic acid. Using the method of fiducial limits, the only insignificant difference was between heparin and chondroitin C, and between hyaluronic acid and pentosan polysulfate. Pentosan polysulfate required significantly higher equilibrium concentration than heparin and hyaluronic acid to cover half of the surface of the calcium oxalate crystals. The principle of Langmuir isotherm adsorption can be useful in predicting the effects of macromolecules on crystallization. Weaker inhibitors bind with less affinity than do stronger inhibitors. Further work is underway to characterize other inhibitors and promoters.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709520     DOI: 10.1016/s0022-5347(17)41233-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

Review 1.  Current status of ureteral stent technologies: comfort and antimicrobial resistance.

Authors:  Carlos E Mendez-Probst; Alfonso Fernandez; John D Denstedt
Journal:  Curr Urol Rep       Date:  2010-03       Impact factor: 3.092

2.  Urinary crystal surface binding substances on calcium oxalate crystals.

Authors:  T Koide; T Yoshioka; S Yamaguchi; S Hosokawa; M Utsunomiya; T Sonoda
Journal:  Urol Res       Date:  1990

3.  Update on ureteral stent technology.

Authors:  Dirk Lange; Ben H Chew
Journal:  Ther Adv Urol       Date:  2009-08

4.  Urinary glycosaminoglycan excretion in healthy and stone-forming children.

Authors:  F Harangi; Z Györke; B Melegh
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

5.  Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine?

Authors:  H Bek-Jensen; A M Fornander; M A Nilsson; H G Tiselius
Journal:  Urol Res       Date:  1996

6.  A simple technique for studying struvite crystal growth in vitro.

Authors:  R J McLean; J Downey; L Clapham; J C Nickel
Journal:  Urol Res       Date:  1990

7.  Heparin sulfate in the stone matrix and its inhibitory effect on calcium oxalate crystallization.

Authors:  S Yamaguchi; T Yoshioka; M Utsunomiya; T Koide; M Osafune; A Okuyama; T Sonoda
Journal:  Urol Res       Date:  1993-05

Review 8.  Glycosaminoglycans and other sulphated polysaccharides in calculogenesis of urinary stones.

Authors:  E R Boevé; L C Cao; C F Verkoelen; J C Romijn; W C de Bruijn; F H Schröder
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

9.  Heparan sulfate gene polymorphism in calcium oxalate nephrolithiasis.

Authors:  Metin Onaran; Akin Yilmaz; Ilker Sen; Mehmet Ali Ergun; Ahmet Camtosun; Bora Küpeli; Sevda Menevse; Ibrahim Bozkirli
Journal:  Urol Res       Date:  2008-12-09

10.  In vitro and in vivo studies on bacteria and encrustation resistance of heparin/poly-L-lysine-Cu nanoparticles coating mediated by PDA for ureteral stent application.

Authors:  Bukola O Awonusi; Jianzhong Li; Hongwei Li; Zhenyu Wang; Ke Yang; Jing Zhao
Journal:  Regen Biomater       Date:  2022-07-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.